Fosun to buy 86% stake in India’s Gland Pharma
Print Edition
SHANGHAI Fosun Pharmaceutical Group Co has agreed to buy an 86 percent stake in Gland Pharma — backed by KKR & Co — for up to US$1.3 billion, India’s largest inbound acquisition this year.
The deal, announced by the Chinese company yesterday, is the first major move by the Fosun group since Guo Guangchang, founder of flagship holding firm Fosun International Ltd and one of China’s best-known entrepreneurs, briefly went missing late last year.
The acquisition, which is subject to regulatory approvals, would also underscore a positive outlook for drugmakers in India, which is a major global supplier and counts the United States as its largest export market, helped by lower manufacturing and labor costs.
Hyderabad-based Gland Pharma owns four factories from where it supplies a variety of injectables — widely used medicines administered through vials, syringes, bags and pumps, which are harder to make than regular medicines.
Moody’s Indian associate ICRA expects patents to expire on about US$16 billion worth of injectables in the United States over four years through 2019, offering a growth opportunity for Indian suppliers. ICRA estimates the US injectables market to grow at about 10 percent annually over five years.
Gland Pharma’s founders and US private equity firm KKR jointly hold roughly 96 percent of the drugmaker.
Shanghai Fosun, in a statement, said it will buy 86.1 percent of Gland, and plans to raise up to US$800 million in loans from financial institutions to help fund the deal.
Fosun group is also looking for opportunities in Britain and Europe, in markets rendered increasingly volatile by Britons’ vote to leave the European Union, Guo said at a Reuters Newsmaker event last month.
Besides Fosun, the Gland Pharma sale attracted interest from private equity firm Advent, medical company Baxter International Inc and drugmaker Torrent Pharmaceuticals Ltd, people close to the matter told Reuters in April.
Opportunities for injectables in the US has attracted large pharmaceutical firms such as Mylan NV, which bought the injectables business of Strides Shasun Ltd in 2013.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
